Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Midazolam Maleate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Neuraxpharm Launches First Product in Japan
Details : Buccolam (oromucosal midazolam), value-added buccal midazolam indicated for emergency treatment of children and adolescents from 3 months to 18 years with epilepsy suffering from prolonged acute convulsive seizures.
Product Name : Buccolam
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 01, 2021
Lead Product(s) : Midazolam Maleate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midazolam Maleate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Permira
Deal Size : $1,880.0 million
Deal Type : Acquisition
Permira Funds to Acquire Leading European CNS Specialty Pharmaceutical Company Neuraxpharm
Details : The Permira funds will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of Neuraxpharm’s attractive new product pipeline and support further its expa...
Product Name : Buccolam
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 22, 2020
Lead Product(s) : Midazolam Maleate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Permira
Deal Size : $1,880.0 million
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Panaxia
Deal Size : Undisclosed
Deal Type : Agreement
Panaxia's Agreement with International Pharma Neuraxpharm is Finalized
Details : The agreement, which anchors a previous MOU entered by the companies, includes exclusivity for Panaxia products, as well as an option for scaling the distribution to additional countries, also including further major European countries.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 22, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Panaxia
Deal Size : Undisclosed
Deal Type : Agreement